{"entities":[{"id":"us-hhs-synthetic-oligonucleotides-draft-2022","name":"Screening Framework Guidance for Providers and Users of Synthetic Oligonucleotides (proposed draft revised guidance)","subtype":"Guidance","description":"As published in the Federal Register of 29 April 2022 (87 FR 25495). Federal Register issue date of the notice.","sourceIds":["source-ab-hhs-2022-fr"]},{"id":"us-hhs","name":"United States Department of Health and Human Services"},{"id":"us-aspr","name":"Administration for Strategic Preparedness and Response (U.S. Department of Health and Human Services)"}],"claims":[{"id":"ab-scr-hhs-2010-all-providers-addressees","attributes":{"provision":{"kind":"threshold","key":"us-hhs-screening-guidance-2010-addressees"}}},{"id":"ab-scr-hhs-2010-effective-date","attributes":{"provision":{"kind":"date","key":"hhs-2010-effective-date"}}},{"id":"ab-scr-hhs-2010-voluntary-all-providers","attributes":{"provision":{"kind":"standing","key":"us-hhs-screening-guidance-2010-voluntary-standing"}}},{"id":"ab-scr-hhs-2022-draft-published","statement":"The Office of the Assistant Secretary for Preparedness and Response published a proposed revised screening framework guidance for providers and users of synthetic oligonucleotides in the Federal Register of 29 April 2022, submitting it for public consideration and comment for a period of 60 days.","derivation":"explicit","resolution":"supported","editorialState":"seed","evidenceIds":["evidence-ab-scr-hhs-2022-draft-published-1","evidence-ab-scr-hhs-2022-draft-published-2"]},{"id":"ab-scr-hhs-2023-benchtop-manufacturers","attributes":{"provision":{"kind":"required_action","key":"us-hhs-screening-guidance-2023-benchtop-manufacturers"}}},{"id":"ab-scr-hhs-2023-provider-screening","attributes":{"provision":{"kind":"required_action","key":"us-hhs-screening-guidance-2023-provider-order-screening"}}},{"id":"ab-scr-hhs-2023-refuse-and-report","attributes":{"provision":{"kind":"required_action","key":"us-hhs-screening-guidance-2023-refusal-and-reporting"}}},{"id":"ab-scr-hhs-2023-scope","attributes":{"provision":{"kind":"threshold","key":"us-hhs-screening-guidance-2023-scope"}}}],"sources":[{"id":"source-ab-hhs-2022-fr","title":"Screening Framework Guidance for Providers and Users of Synthetic Oligonucleotides (87 FR 25495)","authors":["Federal Register (Office of the Federal Register, National Archives) via govinfo.gov"],"publisher":"Federal Register (Office of the Federal Register, National Archives) via govinfo.gov","publicationDate":null,"version":"Retrieved for the candidate pack on 2026-10-28 (SHA-256 57b028801e628b4ba88d1b97b08f9a29e01478a1d905845db087cbb3e06fdd99). Federal Register print of 29 April 2022, Vol. 87, No. 83, FR Doc. 2022-09210: the proposed draft revised guidance published for comment. Retrieved again at admission on 2026-10-30 (SHA-256 57b028801e628b4ba88d1b97b08f9a29e01478a1d905845db087cbb3e06fdd99, the same bytes).","evidenceUrl":"https://www.govinfo.gov/content/pkg/FR-2022-04-29/pdf/2022-09210.pdf","language":"en"}],"evidence":[{"id":"evidence-ab-scr-hhs-2022-draft-published-1","sourceRole":"primary","support":"supports","verification":"machine_checked","retrievalRoute":"direct"},{"id":"evidence-ab-scr-hhs-2022-draft-published-2","support":"supports","verification":"machine_checked","retrievalRoute":"direct"}],"at":{"entities":[1217,1224,1225],"claims":[3282,3283,3285,3286,3293,3294,3296,3297],"sources":[1045],"evidence":[4503,4504]},"version":"1lg47t7"}